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Neisseria gonorrhoeae is the causative agent of gonorrhea, one of the most important sexually transmitted diseases. 
The incidence of gonorrhea is still prevalent and about 50,000 new cases have been reported annually during the late 
2000s in Korea. The antimicrobial resistance of N. gonorrhoeae is very prevalent and most isolates are multi-drug 
resistant to penicillin G, tetracycline, and fluoroquinolones. The incidence of penicillinase-producing N. gonorrhoeae 
(PPNG) decreased significantly, but high-level tetracycline-resistant N. gonorrhoeae (TRNG) increased recently. The 
minimum inhibitory concentrations (MICs) of ceftriaxone were within the susceptible range for all isolates, but MIC 
creep has been apparent and one cefixime-nonsusceptible isolate (0.5 μg/ml) was found. Spectinomycin-resistant isolates 
remain rare, but caution should be required when dealing with gonococcal pharyngitis. 
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Neisseria gonorrhoeae is the causative agent of gonorrhea, 
one of the most important sexually transmitted diseases 
and results in a wide range of diseases from asymptomatic 
infection to severe complications (1). Humans are the only 
hosts of this pathogen, and N. gonorrhoeae is always 
considered pathogenic even in asymptomatic patients. Most 
common type of infection is acute urethritis in men and 
endocervicitis in women, but up to 10% of men and many 
women may be asymptomatic. Most cases of untreated 
infections resolve spontaneously after several weeks, but 
severe complications such as pelvic inflammatory diseases 
and disseminated gonococcal infections may occur. 
The prevalence of N. gonorrhoeae infection has decreased 
in many developed countries during the past few decades 
(2~4), but it is still high in many developing countries (5). 
According to the global estimation by the World Health 
Organization in 2011, 88 million new cases of gonococcal 
infections have been reported annually (6). The incidence of 
gonorrhea seemed to decrease in Korea recently according 
to the data from the Korean Centers for Disease Control 
and Prevention (7), but the data from the Korea Health 
Insurance Review and Assessment Service showed that 
gonorrhea is still prevalent and about 50,000 new cases 
have been reported annually during the late 2000s in Korea. 
Moreover, gonorrhea is very problematic in certain patient 
groups, such as adolescents in youth shelters (8). The preva- 
lence of gonorrhea among university students was as low 
as 0.4% (9), but adolescents who had a sexual experience 
in youth shelters showed very high prevalence of 28% by 
polymerase chain reaction in 2004 in Korea (8). 
Historically, gonorrhea has been a community-acquired 
disease and treated empirically at a primary-care hospital, 
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and it has responded well to antimicrobial agents such as 
penicillin G and fluoroquinolones. However, the emergence 
of antimicrobial resistance in N. gonorrhoeae has compro- 
mised the treatment and control of the disease (10, 11). 
Due to the recent use of molecular diagnostic methods, the 
routine isolation and susceptibility testing of N. gonorrhoeae 
are performed rarely; therefore, it is hard to select optimal 
antibiotics in clinical settings. Therefore, surveillance pro- 
gram of antimicrobial resistance is required to establish the 
guideline for empirical treatment and control of gonococcal 
infection. The antimicrobial resistance of N. gonorrhoeae 
has been a serious problem in Korea (12~17). In this review, 
we discussed the current status of antimicrobial resistance 
of N. gonorrhoeae and of gonococcal infection in Korea. 
 
Penicillin G, tetracycline, and fluoroquinolone 
 
N. gonorrhoeae had been highly-susceptible to penicillin 
G. However, penicillin G lost its clinical usefulness rapidly 
since the clinical treatment failure of penicillin was reported 
in the 1950s in Korea (18). The annual rate of penicillin-
susceptible N. gonorrhoeae collected during 1966-1975 
varied from 7.7% to 26.7%, and the average rate of 
susceptible isolates during that period was only 12.1% in 
Korea (19). Resistance to penicillin G became more serious 
and no susceptible isolates were detected since the 1990s 
(12). Penicillin G resistance in N. gonorrhoeae is due to two 
different mechanisms: one is plasmid-mediated β-lactamase 
production (penicillinase-producing N. gonorrhoeae, PPNG) 
and another is changes in amino acid sequences in 
penicillin-binding protein (PBP) encoded by chromosomes 
(chromosomally-mediated penicillin-resistant N. gonor- 
rhoeae, CMRNG). PPNG produces TEM-1 type β-lactamase, 
which confers high level resistance to penicillin G. The 
prevalence of PPNG increased steadily until the 1990s and 
remained high in many Asian countries as compared to 
most developed countries (20, 21). In Korea, the first case 
of PPNG was isolated in the US armed forces personnel, 
but he had a history of contract with the infection not in 
Korea but in South-East Asia where PPNG appeared for the 
first time (22). The true first case was isolated from 51-year-
old housewife in Seoul in 1979, and it was supposed that 
PPNG occurred within Korea because both the patient and 
her husband had never traveled abroad (22). The proportion 
of PPNG steadily increased during the 1980s and 1990s and 
reached 84% in 1999 (Fig. 1), but decreased rapidly in the 
2000s (12~17). The decline was also reported in other 
countries such as Hong Kong (23~25), but the exact cause 
was not known. Although the prevalence of PPNG de- 
creased, all non-PPNG isolates was non-susceptible to 
penicillin G with elevated minimum inhibitory concen- 
trations (MICs), indicating that penicillin G cannot be used 
to treat gonorrheal infection (14~17). 
Tetracycline is another historical antimicrobial agent 
used to treat gonococcal infection but is no longer used. 
Tetracycline resistance arose from chromosomal mutations 
in tet, penB, and mtrR genes (low-level resistance) and 
acquisition of a conjugative tetM-containing plasmid (high-
level tetracycline-resistant N. gonorrhoeae, TRNG) from 
other isolates (26). Although tetracycline is no longer pre- 
scribed as a treatment option, susceptibility to tetracycline 
can be tested routinely because the isolation trend of 
TRNG may be useful for epidemiologic studies. In Korea, 
tetracycline-susceptible isolates have not been detected since 
the early 1990s (12~17). The rate of TRNG was very low 
until 2004 (14), but the rate increased during the late 2000s 
(15~17) and finally reached to 22% in our 2011 study (Fig. 
1), (unpublished data). The reason for the recent increase of 
TRNG is not clear, but the changes in epidemiology in 
gonococcal infection seemed to have happened and further 
investigation may be required. 
Fluoroquinolones, such as ciprofloxacin and ofloxacin, 
started to be used for gonorrhea in the mid-1980s (27) and 
was one of the recommended drugs in the 1990s (28) 
because it had several advantages: it could be used orally in 
a single dose regimen and was highly concentrated in 
urine (29~31). However, frequent use of fluoroquinolones 
resulted in a wide spread of resistance (31, 32). In Korea, 
fluoroquinolone susceptibility was as high as 91% in 1992, 
but it rapidly decreased to 46% in 1996 (12). With con- 
tinuous decrease of susceptible isolates, the resistance rate 
increased from 20% in 1997 (13) to 88% in 2011 in our 
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present study (Fig. 1), (unpublished data). Fluoroquinolone 
resistance was mainly due to mutations in the target sites: 
the gyrA and parC genes. Most of the fluoroquinolone-
resistant isolates had amino acid substitutions at the 91st 
and 95th positions in GyrA and a single substitution at the 
86th or 87th position in ParC (14, 33). Accumulation of these 
mutations can lead to increased fluoroquinolone resistance. 
Because of rapid and progressive spread of resistance in 
clinical isolates, fluoroquinolones have not been recom- 
mended in the United States and Korea since 2007 (34~ 
36). However, despite discontinuation of the use of fluoro- 
quinolones, the prevalence of fluoroquinolone-resistant N. 
gonorrhoeae has not decreased and novel mutations in the 
gyrA and parC genes continued to be detected. This suggests 
slow but sustained evolution of the genes as a consequence 
of selection for fluoroquinolone resistance due to dual 
therapy for accompanying chlamydial infections. However, 
importation of strains with new QRDR substitutions is a 




Recently, cephalosporins have become one of the most 
active therapeutic choices for gonococcal infection. Cef- 
triaxone, cefotaxime, and cefixime are recommended by 
the Korean guideline for gonorrhea (34). Ceftriaxone is the 
predominantly used cephalosporin antimicrobial agent in 
gonococcal infection because of its high intrinsic activity 
against N. gonorrhoeae together with a long half-life and 
success in eradicating the organism from all sites of infection 
(37). Multi-drug resistance to penicillin G, tetracycline, and 
fluoroquinolone in N. gonorrhoeae led to a slight increase 
in the use of third-generation cephalosporins and spectino- 
mycin in Korea (14). In 2002, only 9.5% of patients were 
treated with cephalosporins including parenteral ceftriaxone 
and oral cefixime. The rate increased to 30% in 2010. As 
cephalosporin is used more often, resistance to cephalos- 
porin in N. gonorrhoeae has emerged (38~42). A recent 
Gonococcal Infection Surveillance Program in the U.S. 
showed an increasing trend of gonococcal isolates with 
Figure 1. Annual trend of rates of penicillinase-producing Neisseria gonorrhoeae (PPNG), highly tetracycline-resistant N. gonorrhoeae
(TRNG), and ciprofloxacin-resistance in N. gonorrhoeae (CIP-R) isolated in Korea 
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elevated MICs of cefixime (≥0.25 μg/ml) from 0.2% in 
2000 to 1.4% in 2010 and of ceftriaxone (≥0.125 μg/ml) 
from 0.1% in 2000 to 0.3% in 2010 (43). Sustained increase 
of MIC to near breakpoint within the susceptible range 
(MIC creep) hinders efficacy of cephalosporin antibiotics 
in gonorrheal treatment. Because the clinical efficacy of 
β-lactam antibiotics is related to the periods for which free 
drug concentration exceeds MIC (f T>MIC), increasing MIC 
decreases f T>MIC and clinical failure can arise. The current 
regimen of ceftriaxone (250 mg) and cefixme (400 mg) 
may be effective, but the MIC creep and resulting reduction 
of f T>MIC may be a cause of clinical failure in gonorrheal 
treatment with ceftriaxone and cefixime MICs of 0.125~ 
0.25 μg/ml (44). 
Ceftriaxone-resistant N. gonorrhoeae was not reported 
until 2011, but two cases of ceftriaxone-resistant isolates 
were reported in Japan (H041 strain, ceftriaxone MIC 2 μg/ 
ml) and France (F89 strain, ceftriaxone MIC 2 μg/ml) in 
2011 (45~47). The mechanism of resistance of these two 
strains was determined and seemed to be associated with 
novel penA mosaicism. In Korea, all isolates were suscep- 
tible to ceftriaxone in an annual successive study that was 
previously performed and supported by the Korea National 
Institute of Health. However, MIC creep was apparent (14): 
more than 32-fold difference was noted between the lowest 
and the highest MICs. The MIC range of ceftriaxone for N. 
gonorrhoeae in our previous study was ≤0.008~0.06 μg/ 
ml during 1997 and 1999 (13), but the upper margin of 
MICs increased to 0.25 μg/ml near the breakpoint in 
isolates collected during the 2000s (14~17). The proportion 
of isolates inhibited by ≥0.06 μg/ml of ceftriaxone in- 
creased from less than 10% of the isolates from 1997-1999 
(13) to 39% of the isolates from 2011 in our present study 
(unpublished data), and this meant 39% of N. gonorrhoeae 
isolated in Korea was not susceptible to ceftriaxone by the 
Australian guideline. 
Ceftriaxone had a good activity in treating gonococcal 
infection, but it had to be given as an intramuscular injection 
that is locally painful and requires co-administration of a 
local anesthetic such as lidocaine. For this reason, the use 
of a number of oral cephalosporins was evaluated. Cefixime 
is one of the orally absorbed cephalosporins that is not only 
active against penicillin-resistant N. gonorrhoeae regardless 
of production of β-lactamase but also has pharmacokinetic 
activity suitable for single-dose administration. In a ran- 
domized unblinded multicenter study reported in 1991, a 
single dose of oral cefixime appeared to be as effective as 
ceftriaxone in the treatment of uncomplicated gonorrhea 
(48). Thereafter, cefixime and other oral cephalosporins such 
as cefuroxime axetil (49), ceftibuten (50), cefoperazone 
(51), cefdinir (52), cefpodoxime proxetil (53), and cefaclor 
(54) were used to treat gonococcal infection in many 
countries. However, an increasing number of treatment 
failures with oral cephalosporin regimens, especially with 
cefixime (55) and ceftibuten (42), were reported recently. 
Treatment failure with cefixime was reported first in 2001 
in Japan, which was 10 years earlier than when ceftriaxone-
resistant N. gonorrhoeae was reported in Japan in 2011. 
Cefixime-resistant N. gonorrhoeae disseminated widely and 
became common in Japan since 2001, and cefixime was no 
longer recommended as a treatment option in Japan (56~ 
59). In Korea, cefixime non-susceptible N. gonorrhoeae 
(cefixime MIC, 0.5 μg/ml) was first isolated in 2004 (60), 
but there was no additional cefixime non-susceptible strain 
isolated in a successive study until 2010. This isolate had the 
identical genetic background and mechanism with isolates 
that were reported to be cefixime resistant in Japan in 2001. 
The mechanism of resistance to cephalosporin has not 
been completely understood yet, but alterations in PBP2 
seem to play an important role in cephalosporin resistance 
in N. gonorrhoeae. When the first cefixime-resistant N. 
gonorrhoeae was reported in Japan in 2001, it was suggested 
that mosaicism (Pattern X) in PBP2 encoded by the penA 
gene was associated with clinical failure and cefixime 
resistance because PBP2 was a main target of β-lactam 
antibiotics in N. gonorrhoeae (55, 61). The relationship 
between PBP2 alteration and cephalosporin susceptibility 
was supported by other studies (58, 61~63). In direct assays, 
mosaic PBP2 showed lower affinity with oral cephalosporins 
including cefixime and cefdinir than that of non-mosaic-
structure PBP2, but affinity with ceftriaxone was not affected 
(61). In the modeling study, the A501V substitution in PBP2 
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also induced a conformational alteration of the β-lactam-
binding pocket such as mosaic PBP2, making a major 
contribution to the reduced susceptibility to cephalosporin 
(58, 62, 63). A recent report on ceftriaxone-resistant N. 
gonorrhoeae showed that novel PBP2 mosaicism (46) 
(97.6% similarity with Pattern X) and A501P substitution 
(47) were also associated with ceftriaxone resistance. 
However, the mechanism of reduced susceptibility was not 
explained by penA mosaicism alone. N. gonorrhoeae with 
the mosaic PBP2 (Pattern X) showed variable MICs for 
cefixime from susceptible to resistant (56), and all N. gonor- 
rhoeae with A501V were still susceptible to ceftriaxone 
despite elevated MICs, suggesting that other genetic changes 
may be needed to provoke resistance to cefixime. Reduced 
susceptibility of N. gonorrhoeae to cephalosporin was 
associated with diverse penA mutations, together with mtrR 
mutations (60). Mutations in the mrtR gene induced the 
derepression of an efflux pump repressor, and these muta- 
tions occurred almost always with an alteration in penB 
gene that encodes porin proteins (64) and in ponA gene that 
encodes PBP1. A mutation in recently identified pilQ gene 
(previously named penC) was also associated with reduced 
susceptibility of cephalosporins (65), but this mutation has 
not been observed in clinical settings. Sequential alterations 
of the penA, mtrR, penB, ponA,and pilQ genes have been 
shown to induce chromosomally mediated high-level 




Spectinomycin is another active antimicrobial agent that is 
cheap and active in uncomplicated gonorrhea (67). However, 
spectinomycin has to be administered as an intramuscular 
injection and can cause treatment failure in gonococcal 
pharyngitis (68). Although spectinomycin resistance had 
been reported in Korea in 1986 and 1993 (51), it has been 
very rare, and spectinomycin-resistant N. gonorrhoeae was 
not isolated in the 2000s (14~17). For this reason, numerous 
gonococcal infections were treated with spectinomycin in 
Korea during the 2000s. However, recent changes in sexual 
behavior may have caused treatment failure in patients with 
gonococcal pharyngitis who are treated with spectinomycin 
(68). These patients may serve as a source of dissemination 
of gonorrhea and provide the means for in-vivo intragenic 
transfer in PBP2 between N. gonorrhoeae and other 




In Korea, the antimicrobial resistance of N. gonorrhoeae 
is very severe and most isolates are multi-drug resistant to 
penicillin G, tetracycline, and fluoroquinolones. The in- 
cidence of PPNG decreased significantly, but the incidence 
of TRNG increased recently. The MICs of ceftriaxone were 
within the susceptible range for all isolates, but MIC creep 
was apparent and one cefixime non-susceptible isolate (0.5 
μg/ml) was found. Almost all isolates were susceptible to 
spectinomycin, but caution should be required when dealing 
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